Search Results - Paul Aisen

Refine Results
  1. 1
    Alzheimer's disease therapeutic research: the path forward

    Alzheimer's disease therapeutic research: the path forward by Paul Aisen

    Published 2009
    Get full text Get full text
    Editorial
    Save to List
    Saved in:
  2. 2
    Advances in Alzheimer’s Disease Drug Development

    Advances in Alzheimer’s Disease Drug Development by Michael S. Rafii, Paul Aisen

    Published 2015
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  3. 3
    Recent developments in Alzheimer's disease therapeutics

    Recent developments in Alzheimer's disease therapeutics by Michael S. Rafii, Paul Aisen

    Published 2009
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  4. 4
    Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease

    Moving towards early clinical trials for amyloid-targeted therapy in Alzheimer's disease by Paul Aisen, Bruno Vellas, Harald Hampel

    Published 2013
    Get full text
    Revisão
    Save to List
    Saved in:
  5. 5
    Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease

    Symptomatic and Nonamyloid/Tau Based Pharmacologic Treatment for Alzheimer Disease by Paul Aisen, Joanne Cummings, L. S. Schneider

    Published 2011
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  6. 6
    Testing the Right Target and Right Drug at the Right Stage

    Testing the Right Target and Right Drug at the Right Stage by Reisa A. Sperling, Clifford R. Jack, Paul Aisen

    Published 2011
    Get full text
    Revisão
    Save to List
    Saved in:
  7. 7
    Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans

    Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans by Paul Aisen, Ronald C. Petersen, Michael Donohue, Michael W. Weiner

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  8. 8
    Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review

    Randomised controlled trials for the prevention of cognitive decline or dementia: A systematic review by Nicola Coley, Caroline Giulioli, Paul Aisen, Bruno Vellas, Sandrine Andrieu

    Published 2022
    Get full text Get full text
    Revisão
    Save to List
    Saved in:
  9. 9
    A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice

    A Humanin Derivative Reduces Amyloid Beta Accumulation and Ameliorates Memory Deficit in Triple Transgenic Mice by Takako Niikura, Elkhansa Sidahmed, Chiho Hirata‐Fukae, Paul Aisen, Yasuji Matsuoka

    Published 2011
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  10. 10
    Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease

    Longitudinal plasma amyloid beta as a biomarker of Alzheimer’s disease by Robert A. Rissman, John Q. Trojanowski, Leslie M. Shaw, Paul Aisen

    Published 2012
    Get full text
    Revisão
    Save to List
    Saved in:
  11. 11
    Effect of study partner on the conduct of Alzheimer disease clinical trials

    Effect of study partner on the conduct of Alzheimer disease clinical trials by Joshua D. Grill, Rema Raman, Karin Ernström, Paul Aisen, Jason Karlawish

    Published 2012
    Get full text
    Artigo
    Save to List
    Saved in:
  12. 12
    The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding

    The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding by Laurel Beckett, Michael Donohue, Cathy Wang, Paul Aisen, Danielle Harvey, Naomi Saito

    Published 2015
    Get full text
    Revisão
    Save to List
    Saved in:
  13. 13
    Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention

    Neuroanatomical spread of amyloid β and tau in Alzheimer’s disease: implications for primary prevention by Philip S. Insel, Elizabeth C. Mormino, Paul Aisen, Wesley K. Thompson, Michael Donohue

    Published 2020
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  14. 14
    Predicting the course of Alzheimer’s progression

    Predicting the course of Alzheimer’s progression by Samuel Iddi, Dan Li, Paul Aisen, Michael S. Rafii, Wesley K. Thompson, Michael Donohue

    Published 2019
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  15. 15
    Aducanumab: Appropriate Use Recommendations

    Aducanumab: Appropriate Use Recommendations by Joanne Cummings, Paul Aisen, Liana G. Apostolova, Alireza Atri, Stephen Salloway, Michael W. Weiner

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  16. 16
    PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease

    PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease by Marwan N. Sabbagh, Albert Agro, J. Simon Bell, Paul Aisen, Edward E. Schweizer, Douglas Galasko

    Published 2010
    Get full text
    Artigo
    Save to List
    Saved in:
  17. 17
    Aducanumab produced a clinically meaningful benefit in association with amyloid lowering

    Aducanumab produced a clinically meaningful benefit in association with amyloid lowering by Jeffrey L. Cummings, Paul Aisen, Cynthia A. Lemere, Alireza Atri, Marwan N. Sabbagh, Stephen Salloway

    Published 2021
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  18. 18
    Health‐Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment

    Health‐Related Resource Use and Costs in Elderly Adults with and without Mild Cognitive Impairment by Carolyn W. Zhu, Mary Sano, Steven H. Ferris, Peter J. Whitehouse, Marian B. Patterson, Paul Aisen

    Published 2013
    Get full text
    Artigo
    Save to List
    Saved in:
  19. 19
    Effect of TTP488 in patients with mild to moderate Alzheimer’s disease

    Effect of TTP488 in patients with mild to moderate Alzheimer’s disease by Aaron H. Burstein, Imogene Grimes, Douglas Galasko, Paul Aisen, Marwan N. Sabbagh, Adnan M.M. Mjalli

    Published 2014
    Get full text Get full text
    Artigo
    Save to List
    Saved in:
  20. 20
    Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease

    Resveratrol regulates neuro-inflammation and induces adaptive immunity in Alzheimer’s disease by Charbel Moussa, Michaeline Hebron, Xu Huang, Jaeil Ahn, Robert A. Rissman, Paul Aisen, Raymond Scott Turner

    Published 2017
    Get full text Get full text
    Artigo
    Save to List
    Saved in:

Search Tools: